Short answer
Greenwich LifeSciences, Inc. (GLSI) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$6M
- −40.0% YoY · −47.2% QoQ
- EPS (diluted)
- −$0.40
- −33.3% YoY · −53.8% QoQ
Source: XBRL data from the Greenwich LifeSciences, Inc. (GLSI) Q3 2026 10-Q on SEC EDGAR. USD.
Greenwich LifeSciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no commercialization achieved
- R&D expenses $5.45M, up 67% from $3.27M, driven by clinical expenses
- G&A expenses $412,695, down 12% from $466,926, following option-grant expirations
- Cash $5.90M vs $6.18M at December 31, 2025, operating cash use $9.62M
- ATM financing net proceeds $9.34M, with 379,762 shares sold at $25.36 average price; additional capital required as losses continue
Risk Factors
- No material changes from Form 10-K risk factors for year ended December 31, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Greenwich LifeSciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.